Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant apalutamide versus standard of care after radical prostatectomy in high-risk localized or locally advanced prostate cancer
2018-004329-10Phase 2Active
- Sponsor
- Universität Münster
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) comparing Apalutamide with Standard of care (2 arms). Primary endpoint: Progression-free survival. Started Feb 2020; status: active.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2018-004329-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004329-10.